Literature DB >> 8319

Hypotensive responses following oral adminstration of beta-adrenoceptor blocking drugs to the conscious cat.

D T Burden, T C Hamilton.   

Abstract

On oral administration, the non-selective beta-adrenoceptor blocking drugs (+/-)-bufuralol, (-)-bufuralol, propanolol, oxprenolol, pindolol and alprenolol produced hypotensive responses in the conscious cat; (+)-bufuralol was without effect. The selective beta-adrenoceptor blocking drugs practolol and atenolol had no effect on blood pressure but tolamolol elicited a hypotensive response. All the drugs tested reduced the tachycardia due to intravenous isoprenaline in the conscious cat; however, not all doses of these drugs reduced blood pressure. (+)-Bufuralol was devoid to beta-adrenoceptive blocking activity. Only tolamolol reduced the pressor response to i.v. phenylephrine in the conscious cat, indicating that alpha-adrenoceptive blocking activity may contribute to its hypotensive action. The results suggest that beta-adrenoceptive blocking activity is necessary for the hypotensive responses of these drugs. However, for the different drugs, there was no correlation between peripheral beta-adrenoceptive blocking activity and hypotensive response.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 8319     DOI: 10.1016/0014-2999(76)90200-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Role of beta 2-adrenoceptor blockade and circulating adrenaline level for the pressor responses to beta-adrenoceptor blocking drugs in rats.

Authors:  N Himori; T Ishimori; K Shiratsuchi; K Tsuneda; A Izumi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-04       Impact factor: 3.000

2.  Cardiac and renovascular effects in the anaesthetized dog of BW A575C: a novel angiotensin converting enzyme inhibitor with beta-adrenoceptor blocking properties.

Authors:  D Cambridge; M V Whiting; G Allan
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.